Effects of pomegranate juice on blood pressure: A systematic review and meta-analysis of randomized controlled trials

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F17%3A10365236" target="_blank" >RIV/00216208:11160/17:10365236 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S1043661816307848" target="_blank" >http://www.sciencedirect.com/science/article/pii/S1043661816307848</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.phrs.2016.11.018" target="_blank" >10.1016/j.phrs.2016.11.018</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effects of pomegranate juice on blood pressure: A systematic review and meta-analysis of randomized controlled trials

Popis výsledku v původním jazyce

Punica granatum L. (Pomegranate) has been claimed to provide several health benefits. Pomegranate juice is a polyphenol-rich fruit juice with high antioxidant capacity. Several studies suggested that pomegranate juice can exert antiatherogenic, antioxidant, antihypertensive, and anti-inflammatory effects. Nevertheless, the potential cardioprotective benefits of pomegranate juice deserve further clinical investigation. To systematically review and meta-analyze available evidence from randomized placebo controlled trials (RCTs) investigating the effects of pomegranate juice consumption and blood pressure (BP). A comprehensive literature search in Medline and Scopus was carried out to identify eligible RCTs. A meta-analysis of eligible studies was performed using a random-effects model. Quality assessment, sensitivity analysisand publication bias evaluations were conducted using standard methods. Quantitative data synthesis from 8 RCTs showed significant reductions in both systolic [weighed mean difference (WMD): -4.96 mmHg, 95% CI: -7.67 to -2.25, p&lt;0.001) and diastolic BP (WMD: -2.01 mmHg, 95% CI: -3.71 to -0.31, p = 0.021) after pomegranate juice consumption. Effects on SBP remained stable to sensitivity analyses. Pomegranate juice reduced SBP regardless of the duration (&gt;12 wks: WMD = -4.36 mmHg, 95% CI: -7.89 to -0.82, p = 0.016) and &lt;12 wks: WMD= 5.83 mmHg, 95% CI: -10.05 to -1.61, p = 0.007) and dose consumed (&gt;240 cc: WMD= -3.62 mmHg, 95% CI: -6.62 to -0.63, p= 0.018) and &lt;240 cc: WMD= -11.01 mmHg, 95% CI: -17.38 to -4.65, p = 0.001, pomegranate juice per day) whereas doses &gt;240 cc provided a borderline significant effect in reducing DBP. The present meta-analysis suggests consistent benefits of pomegranate juice consumption on BP. This evidence suggests it may be prudent to include this fruit juice in a heart-healthy diet.

Název v anglickém jazyce

Effects of pomegranate juice on blood pressure: A systematic review and meta-analysis of randomized controlled trials

Popis výsledku anglicky

Punica granatum L. (Pomegranate) has been claimed to provide several health benefits. Pomegranate juice is a polyphenol-rich fruit juice with high antioxidant capacity. Several studies suggested that pomegranate juice can exert antiatherogenic, antioxidant, antihypertensive, and anti-inflammatory effects. Nevertheless, the potential cardioprotective benefits of pomegranate juice deserve further clinical investigation. To systematically review and meta-analyze available evidence from randomized placebo controlled trials (RCTs) investigating the effects of pomegranate juice consumption and blood pressure (BP). A comprehensive literature search in Medline and Scopus was carried out to identify eligible RCTs. A meta-analysis of eligible studies was performed using a random-effects model. Quality assessment, sensitivity analysisand publication bias evaluations were conducted using standard methods. Quantitative data synthesis from 8 RCTs showed significant reductions in both systolic [weighed mean difference (WMD): -4.96 mmHg, 95% CI: -7.67 to -2.25, p&lt;0.001) and diastolic BP (WMD: -2.01 mmHg, 95% CI: -3.71 to -0.31, p = 0.021) after pomegranate juice consumption. Effects on SBP remained stable to sensitivity analyses. Pomegranate juice reduced SBP regardless of the duration (&gt;12 wks: WMD = -4.36 mmHg, 95% CI: -7.89 to -0.82, p = 0.016) and &lt;12 wks: WMD= 5.83 mmHg, 95% CI: -10.05 to -1.61, p = 0.007) and dose consumed (&gt;240 cc: WMD= -3.62 mmHg, 95% CI: -6.62 to -0.63, p= 0.018) and &lt;240 cc: WMD= -11.01 mmHg, 95% CI: -17.38 to -4.65, p = 0.001, pomegranate juice per day) whereas doses &gt;240 cc provided a borderline significant effect in reducing DBP. The present meta-analysis suggests consistent benefits of pomegranate juice consumption on BP. This evidence suggests it may be prudent to include this fruit juice in a heart-healthy diet.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pharmacological Research

ISSN

1043-6618

e-ISSN

—

Svazek periodika

115

Číslo periodika v rámci svazku

January

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

13

Strana od-do

149-161

Kód UT WoS článku

000392790400013

EID výsledku v databázi Scopus

2-s2.0-84999188049